Rigel Pharmaceuticals (RIGL) Receivables (2013 - 2026)

Rigel Pharmaceuticals' Receivables history runs 13 years deep, the most recent figure standing at $50.9 million for Q1 2026.

• In Q1 2026, Receivables rose 1566.5% year-over-year to $50.9 million; the TTM figure through Mar 2026 stood at $50.9 million (up 1566.5% YoY), while the FY2025 annual figure was $52.7 million, up 26.55% from the prior year.
• Receivables was $50.9 million for Q1 2026 at Rigel Pharmaceuticals, down from $52.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $52.7 million in Q4 2025 to a low of $3.1 million in Q1 2025.
• Historically, Receivables has averaged $29.0 million across 5 years, with a median of $28.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Receivables slumped 89.28% in 2022, then jumped 1566.5% in 2026.
• A 5-year view of Receivables shows it stood at $20.0 million in 2022, then jumped by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then climbed by 26.55% to $52.7 million in 2025, then fell by 3.26% to $50.9 million in 2026.
• The last three Receivables figures came in at $50.9 million (Q1 2026), $52.7 million (Q4 2025), and $46.0 million (Q3 2025), per Business Quant data.